New IV drug for high blood pressure enters early human testing

NCT ID NCT07191899

Recruiting now Disease control Sponsor: Suzhou Alphamab Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called KN060 for people with essential hypertension (high blood pressure). Sixty adults aged 18 to 65 will receive either KN060 or a placebo by IV drip every two weeks for 12 weeks. The main goal is to see if KN060 safely lowers blood pressure compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KN060 (a drug given by intravenous drip every two weeks)
What this could lead to: If it works, this could point toward a new treatment option for high blood pressure that requires only a twice-monthly IV infusion.
What could go wrong: This is a very early Phase 1 trial with only 60 people, so it is primarily testing safety and dosing. The drug may not lower blood pressure effectively, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Locations

Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.